Evidence map›Paper›PMID 30572693›Full record

ReviewMolecules (Basel, Switzerland)2018

Advances in the Synthesis of Lignan Natural Products.

Xianhe Fang, Xiangdong Hu

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Phytochemical Profile and Anticancer Potential ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Synthesis of (±)-Phyltetralin by Cu/Pd-Catalyzed Arylboration.Synlett : accounts and rapid communications in synthetic organic chemistry · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. A Concise Synthesis of Sacidumlignan B.Molecules (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Lignans of Sesame (Molecules (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xianhe FangKey Laboratory of Synthetic and Natural Functional Molecule Chemistry of Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an 710127, China. xianhefang@stumail.nwu.edu.cn.
Xiangdong HuKey Laboratory of Synthetic and Natural Functional Molecule Chemistry of Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an 710127, China. xiangdonghu@nwu.edu.cn.ORCID 0000-0002-8644-6454
Ministry of Education of the People's Republic of China · CN

Funding

National Natural Science Foundation of China 21772153the Key Science and Technology Innovation Team of Shaanxi Province 2017KCT-37
6 · The paper itself

Abstract

Lignans comprise a family of secondary metabolites existing widely in plants and also in human food sources. As important components, these compounds play remarkable roles in plants' ecological functions as protection against herbivores and microorganisms. Meanwhile, foods rich in lignans have revealed potential to decrease of risk of cancers. To date, a number of promising bioactivities have been found for lignan natural products and their unnatural analogues, including antibacterial, antiviral, antitumor, antiplatelet, phosphodiesterase inhibition, 5-lipoxygenase inhibition, HIV reverse transcription inhibition, cytotoxic activities, antioxidant activities, immunosuppressive activities and antiasthmatic activities. Therefore, the synthesis of this family and also their analogues have attracted widespread interest from the synthetic organic chemistry community. Herein, we outline advances in the synthesis of lignan natural products in the last decade.

Indexed as

Biological ProductsChemistry, OrganicLignansBiological ProductsLignanslignannatural productstotal synthesis

Identifiers

PMID30572693
PMCPMC6321261
OpenAlexW2903976500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.